Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
Clark
W
W
Department of Medicines Management, Keele University, UK.
Raftery
J
J
Song
F
F
Barton
P
P
Cummins
C
C
Fry-Smith
A
A
Burls
A
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003424:Crohn Disease / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D004341:Drug Evaluation; D006801:Humans; D000069285:Infliximab; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab